Get started
Author

April L. Gilbert

Observed names: April Gilbert, April L Gilbert, April Lamour Gilbert
ORCID: 0000-0002-8626-1919
Observed ORCID: 0000-0002-8626-1919
OpenAlex ID: A5030856434
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells
2021 · Hila Shaim, Mayra Shanley, et al. · Journal of Clinical Investigation · 265
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells
2025 · Hind Rafei, Rafet Basar, et al. · Nature · 61
Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer
2018 · Corrine Ying Xuan Chua, Priya Jain, et al. · Journal of Controlled Release · 60
Remotely controlled nanofluidic implantable platform for tunable drug delivery
2019 · Nicola Di Trani, Antonia Silvestri, et al. · Lab on a Chip · 58
BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML
2024 · Bijender Kumar, Anand Singh, et al. · Science Translational Medicine · 35
Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study
2018 · Carly S. Filgueira, Giacomo Bruno, et al. · Biomedical Microdevices · 33
Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD
2021 · Mayela Mendt, May Daher, et al. · Frontiers in Immunology · 26
PDF
CD70 CAR NK Cells in the Treatment of Multiple Myeloma
2023 · Paul Lin, Francia C. Reyes Silva, et al. · Blood · 19
CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2025 · Paul Lin, Sunil Acharya, et al. · Blood Cancer Discovery · 7
PDF
Inhibition of the αv integrin-TGF-β axis improves natural killer cell function against glioblastoma stem cells
2020 · Hila Shaim, Mayra Hernandez Sanabria, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
A pharmacokinetic study of GC-1 delivery using a nanochannel membrane device
2017 · Carly S. Filgueira, Andrea Ballerini, et al. · Nanomedicine Nanotechnology Biology and Medicine · 6
Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia
2022 · Bijender Kumar, Vahid Afshar-Kharghan, et al. · Frontiers in Immunology · 3
Data from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al. · 2
Abstract 5199: uPAR-targeting CAR-NK cells enhance cytotoxicity against acute myeloid leukemia
2026 · Xingliang Guo, Nadima Uprety, et al. · Cancer Research
Abstract 5194: Oncolytic virus infected tumors drive AP-1 and IRF signaling in NK cells to sustain anti tumor activity
2026 · Hila Shaim, Cheryl Jiang, et al. · Cancer Research
Figure 4 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Table S2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Supplementary Fig S4 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Figure 1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Supplementary Fig S2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Table S1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Supplementary Fig S5 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Supplementary Fig S1 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Figure 2 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Supplementary Fig S6 from CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models
2026 · Paul Lin, Sunil Acharya, et al.
Works count: 37
Citation count: 581
H-index: 8
I10-index: 8
Year
Topic
Type